Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPAGUM: Empagliflozin Effects on Gut Microbiota in HFpEF
NCT05584319Phase 4Unknown
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF). Status: unknown.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05584319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584319.